secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001213900-26-027026
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar reports Q4 2025 net loss $36.1M ($1.78/sh); cash $245.8M plus $460M Feb 2026 offering
--------------------------------------------------------------------------------

- Revenue Q4 2025 $21.8M vs $29.2M YoY; full year $55.2M vs $98.4M.
- Net loss Q4 2025 $36.1M ($1.78/sh) vs net income $7.3M ($0.52/sh) in Q4 2024; full year net loss $164.1M.
- Cash and investments $245.8M at Dec 31, 2025; subsequent $460M secondary offering and $44M ATM in Feb/Mar 2026.
- Phase 2b data for rezpegaldesleukin in atopic dermatitis and alopecia areata reported; Phase 3 to start Q2 2026.
- Research collaboration with UCSF for NKTR-0165 in multiple sclerosis announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390026027026/0001213900-26-027026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390026027026/ea0281334-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-027026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer